CSPC Pharmaceutical Group (HK:1093) has released an update. CSPC Pharmaceutical Group Limited has issued a profit warning, indicating a ...

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical.

The Anglo-Swedish company said it will pay $100 million upfront plus up to $1.9 billion in milestone payments to CSPC Pharmaceutical Group to license a pre-clinical candidate small molecule ...

AstraZeneca (NASDAQ:AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CSPC Pharmaceutical Group Ltd. has entered into an exclusive license agreement with Astrazeneca plc for the global development, manufacture and commercialization of CSPC’s lipoprotein(a) (Lp[a]) ...

As of 3:48 PM GMT+8. Market Open. On Monday, AstraZeneca plc (NASDAQ:AZN) entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to advance the development ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AI-powered stock picks with a proven track record to beat the S&P 500.

AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases. On Monday, AstraZeneca plc (NASDAQ:AZN) entered into an exclusive ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...